Search results for "cohort study"

showing 10 items of 3811 documents

Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease

2017

Background and Aims: The IFNL3/4 locus influencing innate immunity regulation has been associated with the severity of hepatitis and fibrosis progression during chronic hepatitis C infection, while contrasting results were reported in NAFLD. In this study, we examined whether rs12979860 and the linked causal rs368234815 variant encoding for the alternative IFNL4 protein variant are associated with liver fibrosis and damage in a large multicenter cohort of patients at risk of NASH. To clarify the mechanism, we also evaluated the impact on interferon-stimulated gene (ISG) hepatic expression in a subset of patients. Methods: We considered 946 consecutive Italian individuals at risk of NASH wit…

0301 basic medicineHepatitismedicine.medical_specialtyNAFLD NASH IFNL4Hepatologybusiness.industryLocus (genetics)medicine.diseaseGastroenterology03 medical and health sciences030104 developmental biology0302 clinical medicineFibrosisInternal medicineNonalcoholic fatty liver diseaseCohortGenotypemedicine030211 gastroenterology & hepatologyAllelebusinessProspective cohort studyHepatology
researchProduct

Incidence trends of vulvar squamous cell carcinoma in Italy from 1990 to 2015

2020

The incidence of vulvar squamous cell carcinoma has increased for decades in most Western countries - a trend virtually restricted to women aged50 or 60 years. In southern Europe, conversely, the trends have been insufficiently studied. This article reports a study from Italy.Thirty-eight local cancer registries, currently covering 15,274,070 women, equivalent to 49.2% of the Italian national female population, participated. Invasive cancers registered between 1990 and 2015 with an International Classification of Diseases for Oncology, 3rd revision, topography code C51 and morphology codes compatible with vulvar squamous cell carcinoma (n = 6294) were eligible. Incidence trends were analyse…

0301 basic medicineHistoryVulvar Squamous Cell CarcinomaAge-period-cohort modelling; Incidence; Trend; Vulvar neoplasms; Carcinoma Squamous Cell; Female; History 20th Century; History 21st Century; Humans; Incidence; Italy; Middle Aged; Vulvar NeoplasmsSettore MED/42 - Igiene Generale E ApplicataHistory 21st CenturyNO03 medical and health sciences0302 clinical medicineAge-period-cohort modellingAge-period-cohort modelling; Incidence; Trend; Vulvar neoplasmsTrendHumansMedicineRisk factorVulvar neoplasmVulvar Neoplasmsbusiness.industryIncidenceIncidence (epidemiology)CarcinomaObstetrics and GynecologyHistory 20th CenturyMiddle Aged21st CenturyConfidence intervalCancer registry20th CenturyTrend analysis030104 developmental biologySquamous CellItalyOncology030220 oncology & carcinogenesisVulvar neoplasms incidence trend age-period-cohort modellingCarcinoma Squamous CellFemalebusinessDemographyCohort studyGynecologic Oncology
researchProduct

Risk factors for anastomotic leakage after colorectal resection in ovarian cancer surgery: A multi-centre study.

2019

Objective. To determine pre-/intraoperative risk factors for anastomotic leak after modified posterior pelvic exenteration (MPE) or colorectal resection in ovarian cancer and to create a practical instrument for predicting anastomotic leak risk. Background. In advanced ovarian cancer surgery, there is rather limited published evidence, drawn from a small sample, providing information about risk factors for anastomotic leak. Methods. Eight hospitals participated in this retrospective study. Data on 695 patients operated for ovarian cancer with primary anastomosis were included (January 2010-June 2018). Twelve pre-/intraoperative variables were analysed as potential independent risk factors f…

0301 basic medicineLeakmedicine.medical_specialtyMultivariate analysisAnastomotic LeakAnastomosisStoma03 medical and health sciences0302 clinical medicineOvarian cancerRetrospective StudieRisk FactorsIntestine SmallmedicineAnastomotic leakHumansAge FactorColectomySerum AlbuminAgedRetrospective StudiesOvarian NeoplasmsProctectomybusiness.industryIncidence (epidemiology)Ovarian NeoplasmRisk FactorAnastomosis SurgicalSuture TechniquesAge FactorsObstetrics and GynecologyRetrospective cohort studyMiddle Agedmedicine.diseasePosterior Pelvic ExenterationSurgeryPelvic Exenteration030104 developmental biologyRisk factorsOncology030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalOvarian cancerbusinessHumanGynecologic oncology
researchProduct

Dietary components modulate the risk of hepatocellular carcinoma in cirrhotic patients.

2018

Abstract Eighty percent of hepatocellular carcinoma (HCC) cases occur after cirrhosis from various etiologies. The association between diet and cancer is well accepted, but the links with cirrhosis progression and HCC risk have been poorly investigated. However, we hypothesized that diet could be a modifiable preventive factor for HCC. Thus, the aim of our study was to explore the relationships between dietary factors and the risk of HCC in a population of cirrhotic patients. A total of 582 cirrhotic patients were studied: 401 without HCC (controls) and 181 with HCC (cases). These patients were recruited between 2008 and 2012 for the “CiRCE” case-control study conducted in six French univer…

0301 basic medicineLiver CirrhosisMale*Diet/adverse effectsCirrhosisEndocrinology Diabetes and MetabolismGastroenterologyFood groupchemistry.chemical_compound0302 clinical medicineEndocrinologyDiet and cancerRisk FactorsOdds RatioProspective StudiesProspective cohort study*Case-control studyeducation.field_of_studyNutrition and DieteticsLiver NeoplasmsMiddle Aged3. Good healthHepatocellular carcinomaFemale*Feeding Behavior*Hepatocellular carcinomaFranceLiver Neoplasms/etiology/*prevention and controlVitaminmedicine.medical_specialtyCarcinoma Hepatocellular*CirrhosisPopulation030209 endocrinology & metabolism*Diet03 medical and health sciencesHepatocellular/etiology/*prevention and controlInternal medicinemedicineDiabetes MellitusHumanseducationLiver Cirrhosis/complications/*diet therapyAged030109 nutrition & dieteticsbusiness.industryCarcinomaCase-control studyFeeding Behaviormedicine.diseaseDietLogistic ModelschemistryCase-Control StudiesbusinessEnergy Intake[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyNutrition research (New York, N.Y.)
researchProduct

MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals

2017

AbstractNonalcoholic fatty liver disease (NAFLD) represents an emerging cause of hepatocellular carcinoma (HCC), especially in non-cirrhotic individuals. The rs641738 C > T MBOAT7/TMC4 variant predisposes to progressive NAFLD, but the impact on hepatic carcinogenesis is unknown. In Italian NAFLD patients, the rs641738 T allele was associated with NAFLD-HCC (OR 1.65, 1.08–2.55; n = 765), particularly in those without advanced fibrosis (p < 0.001). The risk T allele was linked to 3’-UTR variation in MBOAT7 and to reduced MBOAT7 expression in patients without severe fibrosis. The number of PNPLA3, TM6SF2, and MBOAT7 risk variants was associated with NAFLD-HCC independently of clinical fa…

0301 basic medicineLiver CirrhosisMaleAlcoholic liver diseasePathologyCirrhosisliver diseasesGastroenterology0302 clinical medicineSettore BIO/13 - Biologia ApplicataNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver diseasefatty liver-disease; cirrhosis; liver cancer; hepatitis C; hepatocellular carcinoma; liver diseases; fibrosis; carcinogenesis; fatty liver; allelesHCCProspective cohort studySettore MED/12 - GastroenterologiaMultidisciplinaryLiver NeoplasmsQRhepatocellular carcinomaSingle NucleotideMiddle Aged3. Good healthItalyfatty liver-diseaseHepatocellular carcinomaCohortMedicine030211 gastroenterology & hepatologyFemalecarcinogenesisAcyltransferases; Adult; Aged; Carcinoma Hepatocellular; Female; Gene Expression Regulation; Genotype; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Male; Membrane Proteins; Middle Aged; Non-alcoholic Fatty Liver Disease; Polymorphism Single Nucleotide; Risk Factors; Alleles; Genetic Association Studies; Genetic Predisposition to Disease; Genetic VariationAdultmedicine.medical_specialtyCarcinoma HepatocellularGenotypeSciencePolymorphism Single NucleotideArticleliver cancer03 medical and health sciencesInternal medicinemedicineHumansGenetic Predisposition to DiseaseAllelePolymorphismAllelesGenetic Association Studiesfatty liverAgedSettore MED/06 - ONCOLOGIA MEDICAbusiness.industrycirrhosisfibrosisCarcinomaGenetic VariationMembrane ProteinsHepatocellularmedicine.diseasedigestive system diseases030104 developmental biologyGene Expression Regulationhepatitis CbusinessAcyltransferasesTM6SF2Scientific Reports
researchProduct

Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disea…

2016

Background The clinical determinants of fibrosis progression in nonalcoholic fatty liver disease (NAFLD) are still under definition. Aim To assess the clinical determinants of fibrosis progression rate (FPR) in NAFLD patients with baseline and follow-up histological evaluation, with a special focus on the impact of pharmacological therapy. Methods In an observational cohort of 118 Italian patients from tertiary referral centers, liver histology was evaluated according to Kleiner. Independent predictors of FPR were selected by a stepwise regression approach. Results Median follow-up was 36 months (IQR 24–77). Twenty-five patients (18%) showed some amelioration, 63 (53%) had stability, 30 (25…

0301 basic medicineLiver CirrhosisMalePeptide HormonesBiopsyTertiary Care Centerlcsh:MedicineBlood PressureAngiotensin-Converting Enzyme InhibitorsType 2 diabetesGastroenterologyVascular MedicineBiochemistryRenin-Angiotensin SystemTertiary Care Centers0302 clinical medicineFibrosisRetrospective StudieNon-alcoholic Fatty Liver DiseaseNonalcoholic fatty liver diseaseMedicine and Health SciencesEthnicitieslcsh:ScienceDiureticsMultidisciplinarymedicine.diagnostic_testMedicine (all)Liver DiseasesFatty liverAngiotensin Receptor AntagonistMiddle AgedPrognosisMetforminMetforminItalian PeopleItalyLiverHypertensionDisease Progression030211 gastroenterology & hepatologyFemaleAnatomymedicine.drugHumanResearch ArticleAdultmedicine.medical_specialtyHistologyPrognosiLiver CirrhosiAdrenergic beta-AntagonistsSurgical and Invasive Medical ProceduresGastroenterology and HepatologyFollow-Up Studie03 medical and health sciencesAngiotensin Receptor AntagonistsInternal medicineDiabetes mellitusBiopsymedicineDiureticHumansRetrospective StudiesBiochemistry Genetics and Molecular Biology (all)business.industrylcsh:RAdrenergic beta-Antagonistnutritional and metabolic diseasesBiology and Life SciencesRetrospective cohort studyAngiotensin-Converting Enzyme Inhibitormedicine.diseaseFibrosisHormonesFatty Liver030104 developmental biologyEndocrinologyAgricultural and Biological Sciences (all)Diabetes Mellitus Type 2People and Placeslcsh:QPopulation GroupingsHydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessDevelopmental BiologyFollow-Up StudiesPLoS ONE
researchProduct

Dietary intake and major food sources of polyphenols in people with type 2 diabetes: The TOSCA.IT Study

2018

Purpose: Proper evaluation of polyphenols intake at the population level is a necessary step in order to establish possible associations with health outcomes. Available data are limited, and so far no study has been performed in people with diabetes. The aim of this work was to document the intake of polyphenols and their major food sources in a cohort of people with type 2 diabetes and in socio-demographic subgroups. Methods: We studied 2573 men and women aged 50–75 years. Among others, anthropometry was measured by standard protocol and dietary habits were investigated by food frequency questionnaire (EPIC). The intake of polyphenols was evaluated using US Department of Agriculture and Ph…

0301 basic medicineMaleAge BMI Diabetes Diet Flavonoids Food groups Geographical area Intake Phenolic acids Polyphenols TOSCA.IT study Aged Antioxidants Beverages Cinnamates Cohort Studies Cross-Sectional Studies Databases Factual Diabetes Mellitus Type 2 Female Flavonoids Fruit Glycosides Humans Italy Male Middle Aged Nutritive Value Phenols Polyphenols Diet Diabetic Diet Healthy Patient ComplianceSettore MED/09 - Medicina InternaDatabases FactualCross-sectional studyMedicine (miscellaneous)Type 2 diabetesDiabeteAntioxidantsSettore MED/13 - EndocrinologiaFood groupCohort Studies0302 clinical medicineDiet DiabeticMedicineFood scienceGlycosidesAge; BMI; Diabetes; Diet; Flavonoids; Food groups; Geographical area; Intake; Phenolic acids; Polyphenols; TOSCA.IT study; Medicine (miscellaneous); Nutrition and DieteticsNutrition and DieteticsPhenolic acidDiabetesfood and beveragesMiddle AgedPolyphenols Flavonoids Phenolic acids Diabetes Food groups Diet Age BMI Geographical area Intake TOSCA.IT studyItalyToscaAgeBMIDiabetesDietFlavonoidsFood groupsGeographical areaIntakePhenolic acidsPolyphenolsTOSCA.IT studyCohortIntakeFemaleDiet HealthyNutritive ValueCohort studyPolyphenolPhenolic acids030209 endocrinology & metabolismBeverages03 medical and health sciencesBMIAgePhenolsDiabetes mellitusHumansAgedFlavonoidsGeographical area030109 nutrition & dieteticsbusiness.industryTOSCA.IT studyPolyphenolsAnthropometrymedicine.diseaseFood groupDietToscaCross-Sectional StudiesDiabetes Mellitus Type 2Food groupsPolyphenolCinnamatesAge; BMI; Diabetes; Diet; Flavonoids; Food groups; Geographical area; Intake; Phenolic acids; Polyphenols; TOSCA.IT studyFruitFlavonoidPatient Compliancebusiness
researchProduct

The Older Finnish Twin Cohort : 45 Years of Follow-up

2019

AbstractThe older Finnish Twin Cohort (FTC) was established in 1974. The baseline survey was in 1975, with two follow-up health surveys in 1981 and 1990. The fourth wave of assessments was done in three parts, with a questionnaire study of twins born during 1945–1957 in 2011–2012, while older twins were interviewed and screened for dementia in two time periods, between 1999 and 2007 for twins born before 1938 and between 2013 and 2017 for twins born in 1938–1944. The content of these wave 4 assessments is described and some initial results are described. In addition, we have invited twin-pairs, based on response to the cohortwide surveys, to participate in detailed in-person studies; these …

0301 basic medicineMaleAgingHORMONE-REPLACEMENT THERAPYphysical activityBLOOD-PRESSURECohort Studies0302 clinical medicineSurveys and QuestionnairesTwins Dizygotickohonnut verenpaineMedicinekohorttitutkimusGenetics (clinical)FinlandBiological Specimen BanksAged 80 and overalcohol1184 Genetics developmental biology physiologyObstetrics and GynecologytwinsMiddle AgedBiobankPOPULATION-BASED TWINepigenetiikkaDEPRESSIVE SYMPTOMSCohortSKELETAL-MUSCLEFemalefyysinen aktiivisuusCohort studyAdulthypertensionAlcohol DrinkinglongitudinalPhysical activityreviewPAIRS DISCORDANTpitkittäistutkimussmokingENVIRONMENTAL-INFLUENCES03 medical and health sciencesTIME PHYSICAL-ACTIVITYtupakointiDiseases in Twinscohort studyDementiaHumansGENOME-WIDE ASSOCIATIONalkoholi (päihteet)Depressive symptomsQuestionnaire studyAgedkaksostutkimusepigeneticsbusiness.industryagingBaseline surveyTwins Monozygoticmedicine.diseasekaksoset030104 developmental biologyikääntyminenPediatrics Perinatology and Child HealthTELOMERE LENGTHbusiness030217 neurology & neurosurgeryDemographyFollow-Up Studiesdementia
researchProduct

Initial serum thyroid peroxidase antibodies and long-term outcomes in SREAT.

2015

Objective To quantify clinical outcome in patients with steroid-responsive encephalopathy and associated autoimmune thyroiditis (SREAT) after the acute phase and explore potential associations of initial serum thyroid peroxidase antibody titers (TPO-Abs) with outcome. Materials and methods Retrospective chart review of patients diagnosed with SREAT between 01/2005 and 05/2014 in a tertiary care center and followed in an affiliated autoimmune outpatient clinic. Outcome was quantified using the extended Glasgow Outcome Scale (GOS-E). We calculated Pearson's correlation coefficients to quantify associations with clinical outcome at follow-up. Results Among 134 patients with encephalopathy of u…

0301 basic medicineMaleAnti-Inflammatory AgentsGlasgow Outcome Scaleblood [Iodide Peroxidase]0302 clinical medicineblood [Hashimoto Disease]blood [Encephalitis]Outpatient clinicHashimoto Diseasebiologytherapy [Hashimoto Disease]Glasgow Outcome Scaletherapy [Encephalitis]therapeutic use [Anti-Inflammatory Agents]General MedicineMiddle Agedblood [Thyroiditis Autoimmune]Magnetic Resonance Imagingtherapy [Thyroiditis Autoimmune]Treatment OutcomeNeurologyEncephalitisFemaleSteroidsImmunosuppressive AgentsAdultmedicine.medical_specialtyEncephalopathyHashimoto DiseaseIodide PeroxidaseAutoimmune thyroiditisanalysis [Autoantibodies]03 medical and health sciencesimmunology [Thyroiditis Autoimmune]Thyroid peroxidaseInternal medicinemedicineHumansddc:610immunology [Encephalitis]therapeutic use [Steroids]AgedAutoantibodiesRetrospective Studiesbusiness.industrytherapeutic use [Methotrexate]Thyroiditis AutoimmuneRetrospective cohort studymedicine.diseasetherapeutic use [Immunosuppressive Agents]immunology [Hashimoto Disease]030104 developmental biologyMethotrexateImmunologybiology.proteinEtiologyNeurology (clinical)businessimmunology [Iodide Peroxidase]030217 neurology & neurosurgeryFollow-Up StudiesActa neurologica Scandinavica
researchProduct

Six year adalimumab efficacy in steroid-dependent Crohn's disease patients: A prospective single-center real life study.

2016

Abstract Background Adalimumab is effective in the treatment of Crohn's disease. We have already reported data on the efficacy of adalimumab in 110 steroid-dependent patients. At the end of the study 90 patients (64.5%) maintained clinical remission. Aims To assess efficacy and safety of adalimumab after 6 years in patients of the original cohort who responded to treatment. Methods The present study is an extension of the published paper on 90/110 patients. We report results on clinical remission and safety of 6 year maintenance therapy with adalimumab. Results Of the original cohort 90 patients completed the study, 17 were lost to follow-up and 3 died. At the end of follow-up (74.16 ± 10.3…

0301 basic medicineMaleAnti-Inflammatory AgentsKaplan-Meier EstimateSingle CenterInflammatory bowel diseaseInflammatory bowel disease0302 clinical medicineMaintenance therapyCrohn DiseaseLong term therapyProspective Studiesskin and connective tissue diseasesProspective cohort studyMultivariate AnalysiCrohn's diseaseRemission InductionGastroenterologyMiddle AgedCrohn's diseaseAnti-Inflammatory AgentTreatment OutcomeItalyCohort030211 gastroenterology & hepatologyFemaleSteroidsHumanmedicine.drugmusculoskeletal diseasesAdultmedicine.medical_specialtySteroid dependencyMaintenance Chemotherapy03 medical and health sciencesInternal medicinemedicineAdalimumabHumansAdverse effectSteroidHepatologybusiness.industryAdalimumabmedicine.diseaseSurgeryProspective Studie030104 developmental biologyMultivariate AnalysisbusinessDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct